Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort Aims: Solid papillary breast carcinoma resembling the tall cell variant of papillary thyroid neoplasms (BPTC), also known as solid papillary carcinoma with reverse polarity, is a rare histological type of breast cancer that resembles morphologically the tall cell variant of papillary thyroid carcinoma. BPTCs are characterised by IDH2 R172 hotspot somatic mutations or mutually exclusive TET2 somatic mutations, concurrently with mutations affecting PI3K pathway-related genes. We sought to characterise their histology and investigate the frequency of IDH2 and PIK3CA mutations in an independent cohort of BPTCs, as well as in conventional solid papillary carcinomas (SPCs).
Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort Aims: Solid papillary breast carcinoma resembling the tall cell variant of papillary thyroid neoplasms (BPTC), also known as solid papillary carcinoma with reverse polarity, is a rare histological type of breast cancer that resembles morphologically the tall cell variant of papillary thyroid carcinoma. BPTCs are characterised by IDH2 R172 hotspot somatic mutations or mutually exclusive TET2 somatic mutations, concurrently with mutations affecting PI3K pathway-related genes. We sought to characterise their histology and investigate the frequency of IDH2 and PIK3CA mutations in an independent cohort of BPTCs, as well as in conventional solid papillary carcinomas (SPCs).
Methods and results: Six BPTCs, not previously analysed molecularly, and 10 SPCs were reviewed centrally.
Tumour DNA was extracted from microdissected histological sections and subjected to Sanger sequencing of the IDH2 R172 hotspot locus and exons 9 and 20 of PIK3CA. All six BPTCs were characterised by solid, papillary and follicular architecture with circumscribed, invasive tumour nodules composed of epithelial cells with reverse polarity. IDH2 mutations were identified in all six BPTCs (three R172S, two R172T and one R172G), four of which also harboured PIK3CA mutations (two H1047R, one Q546K and one Q546R). By contrast, all SPCs lacked IDH2 mutations, while
Introduction
Solid papillary breast carcinoma resembling the tall cell variant of papillary thyroid neoplasms (BPTC), 1 also known as breast tumour resembling the tall cell variant of papillary thyroid carcinoma 2, 3 or solid papillary carcinoma with reverse polarity, 4 is a rare and distinctive subtype of invasive breast cancer. First recognised because of striking similarities with papillary thyroid carcinomas (PTCs), 3 including nuclear diagnostic features (e.g. nuclear grooves and intranuclear pseudo-inclusions), BPTCs were catalogued further under different terminologies, all of which are synonyms. Despite histological similarities to papillary thyroid neoplasms, clinical, immunohistochemical and genetic data indicate that BPTCs are primary breast tumours, given the lack of expression of thyroid-specific markers, including thyroid transcription factor 1 (TTF1) and thyroglobulin, 3, 5, 6 and somatic genetic alterations typically found in PTCs, including those affecting RET/PTC and BRAF 3, [6] [7] [8] Histologically, BPTCs are characterised by circumscribed tumour nodules lacking a peripheral layer of myoepithelial cells growing in solid, papillary and/or follicular architectural patterns. 1, 5, 6 The term 'reverse polarity' stems from the tumour cells harbouring nuclei at the apical rather than the basal pole, thereby creating the impression of reverse polarisation. 4 The polarisation of the cells, however, is preserved, with expression of mucin 1 (MUC1) being found at the apical luminal border. 4 To date, 40 such tumours have been reported. [1] [2] [3] [4] [5] [6] BPTCs are mainly of triple-negative phenotype, with a third being weakly oestrogen receptor (ER)-positive/human epidermal growth factor receptor (HER2)-negative. 1, [3] [4] [5] [6] Clinically, the majority of BPTCs display an indolent biological behaviour with an excellent prognosis; only two reported cases displayed axillary lymph node metastasis. 1, 3, 5, 6 We have demonstrated previously that BPTCs constitute a discrete subtype of breast cancer underpinned by highly recurrent IDH2 R172 hotspot somatic mutations or TET2 loss-of-function somatic mutations, alongside PI3K pathway-related genes. 4 As in leukaemias, 9 IDH2 and TET2 mutations were found to be mutually exclusive in BPTCs, 4 functioning as alternative genetic drivers. In-vitro studies demonstrated that expression of IDH2 mutations in non-malignant breast epithelial cells results in a phenotype closely recapitulating that of BPTCs. While Bhargava et al. recently described IDH2 R172 mutations in two of three additional BPTCs, 2 to the best of our knowledge, IDH2 R172 mutations, which are common in hematological malignancies and brain tumours, 10 have not been described in other breast cancer subtypes. [11] [12] [13] Here, we sought to characterise the unique histology of BPTCs further and investigate the frequency of IDH2 and PI3K catalytic subunit alpha (PIK3CA) hotspot mutations in an independent series of BPTCs, as well as in conventional solid papillary carcinomas (SPCs) to define their potential genetic relatedness.
Methods

C O H O R T
After obtaining approval by the Institutional Review Boards and the local research ethics committees from the authors' institutions, six BPTCs, not previously analysed molecularly, and 10 SPCs were retrieved, reviewed centrally by three breast pathologists (F.C.G., F.P. and E.B.) and anonymised prior to analysis. Three cases were reported previously by Foschini et al.
1 (BPTC14, BPTC15, BPTC17).
M I C R O D I S S E C T I O N A N D D N A E X T R A C T I O N
Representative sections of formalin-fixed paraffinembedded BPTCs and SPCs were subjected to microdissection to ensure > 80% tumour content, as described previously, 14, 15 and DNA was extracted.
I M M U N O H I S T O C H E M I S T R Y ( I H C )
IHC data [cytokeratin (CK) 5/6, p63 and/or calponin] from BPTC14, BPTC15 and BPTC17 was retrieved from Foschini et al. 1 Representative histological sections of BPTC18, BPTC19 and BPTC20 were analysed for CK5/6, p63 and/or smooth muscle myosin heavy chain, as described previously 16 (Supporting information, Table S1 ). Positive and negative controls were included in each slide run. ER, PR and HER2 IHC data were retrieved from original pathology reports for all cases.
The IDH2 R172 hotspot residue and exons 9 and 20 of PIK3CA were investigated in the cohort of BPTCs and SPCs by Sanger sequencing, as described previously (Supporting information, Table S2 ).
15,17
Results
C L I N I C O P A T H O L O G I C A L C H A R A C T E R I S T I C S O F B P T C
The six BPTCs occurred in female patients, with a median age at diagnosis of 60 years (range = 58-85 years). Tumour size ranged from 0. Table S3 ).
B P T C S H A R B O U R H I G H L Y R E C U R R E N T M U T A T I O N S A F F E C T I N G I D H 2 A N D P I K 3 C A
Given that our previous study 4 identified highly recurrent mutations affecting the IDH2 R172 hotspot residue and PIK3CA hotspots in BPTCs, we sought to define the frequencies of these mutations in an independent set of BPTCs. Sanger sequencing analysis revealed high mutation frequencies in both genes ( Figure 2 ). IDH2 R172 hotspot mutations were found in 100% of BPTCs (six of six; three R172S, two R172T and one R172G). PIK3CA hotspot mutations were found in 67% of BPTCs (four of six; two H1047R, one Q546K and one Q546R). These findings are consistent with our previous study, which identified IDH2 R172 hotspot and PIK3CA hotspot mutations in 77 and 69% of BPTCs, respectively, and concurrent IDH2 R172 hotspot and PIK3CA mutations in 62% of BPTCs. 4 In contrast, all conventional SPCs lacked IDH2 R172 hotspot mutations (none of 10 versus six of six BPTCs, P < 0.001, Fisher's exact test), and 10% harboured a PIK3CA hotspot mutation (H1047R; one of 10 versus four of six BPTCs, P = 0.035, Fisher's exact test; Supporting information, Figure S2 ).
Discussion
Here we confirm that BPTC constitutes a rare histological type of breast cancer, with unique morphological features and underpinned by highly recurrent IDH2 R172 mutations alongside PIK3CA mutations. Yet to be recognised as a special type of breast cancer by the World Health Organisation (WHO) classification of breast tumours, 18 our previous 4 and current findings, together with those by Bhargava et al. 2 , establish BPTC as a distinct histological type of invasive breast carcinoma, driven by mutually exclusive genetic alterations affecting the IDH2 R172 hotspot residue or TET2, in conjunction with mutations in PI3K pathway-related genes. Using in-vitro studies, we have shown previously that expression of mutant IDH2 in PIK3CA-mutant breast epithelial cells results in the characteristic phenotype of BPTC. 4 While PI3K pathway-related gene mutations are common in breast cancer, [11] [12] [13] IDH2 mutations are vanishingly rare or non-existent in other breast tumours. [11] [12] [13] Indeed, the conventional SPCs analysed here lacked IDH2 R172 mutations, consistent with their driver role in the pathogenesis of BPTCs, and with the notion that BPTC should not be perceived as a histological variant of SPC.
The mechanism by which IDH2 contributes to tumorigenesis has yet to be understood fully. IDH2 mutations result in loss of catalytic activity and production of a-ketoglutarate (a-KG) and gain of new activity with production of the oncometabolite R-2-hydroxylglutarate (R-2-HG).
19-22
R-2-HG competitively inhibits activity of a-KG-dependent dioxygenases, altering genome-wide histones and DNA methylation and resulting in abnormal epigenetic regulation, cell differentiation and tumorigenesis. 21, 22 Importantly, IDH2-mutant BPTCs display a hypermethylated profile and higher expression levels of H3K27me3 compared to conventional forms of invasive breast cancer. 4 Importantly, however, the mechanism by which IDH2 R172 hotspot mutations or TET2 inactivating mutations alongside PI3K pathway-related gene mutations result in phenotypic features similar to those found in BPTC remains to be defined.
The identification of BPTC in clinical practice carries important implications. BPTCs ought to be distinguished from conventional ER-positive SPCs, but still recognised as a primary invasive neoplasm of the breast requiring complete surgical excision. While its infiltrative nature may be best ascertained with immunohistochemistry, 1 its immunoprofile with CK5/ 6 expression and non-homogeneous cytomorphology may be interpreted as evidence of a hyperplastic process. 2 Interestingly, a link between BPTC and infiltrating epitheliosis, a complex sclerosing lesion with overt, CK5/6-positive epithelial proliferation, 16 has been hypothesised due to similarities in immunoprofile. 2 While recurrent PIK3CA mutations have been documented in infiltrating epitheliosis, IDH2 gene status has yet to be investigated. 16 Furthermore, BPTCs ought to be distinguished from breast secretory carcinomas, which display a similar triple-negative phenotype and CK5/6 expression. Finally, although the number of BPTCs with adequate follow-up is limited, their outcome appears to be excellent despite the triple-negative or weakly ER-positive phenotype. 1, 2 Hence, patients with BPTCs are probably managed adequately without adjuvant systemic therapy. Given that IDH2 R172 mutations are probably pathognomonic of BPTC in the context of breast carcinomas, their identification may be used as a confirmatory molecular finding.
This study has several limitations. First, given the rarity of BPTC, the number of cases analysed is small. Despite this, we validated the high frequency of IDH2 and PIK3CA mutations. Secondly, our results are limited to the selected IDH2 and PIK3CA hotspot residues, hence we cannot exclude the possibility of additional concurrent genetic alterations in BPTCs, such as a concurrent mutation in a PI3K pathwayrelated gene in the PIK3CA wild-type cases. Finally, further analyses of larger cohorts are warranted to define the driver genetic alterations of BPTCs lacking IDH2 or TET2 mutations.
Despite these limitations, our study has confirmed the histological and genetic features that characterise BPTCs, validating the high frequencies of mutations affecting IDH2 and PIK3CA reported previously, 4 and demonstrating the genotypical-phenotypical correlation that characterises this unique breast cancer subtype of favourable prognosis. As somatic mutations affecting IDH2 R172 are vanishingly rare in other breast tumours, they may be employed as ancillary molecular markers in the diagnosis of BPTC. Figure 2 . IDH2 R172 hotspot and PIK3CA hotspot mutations identified by Sanger sequencing analysis in solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (BPTCs). Representative sequence electropherograms of the IDH2 R172 hotspot and exons 9 and 20 of PIK3CA identified by Sanger sequencing in the six BPTCs studied.
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